Novartis Aims For 14 New Blockbuster Drugs By End Of 2017
This article was originally published in The Pink Sheet Daily
At an investor day presentation Nov. 8, Novartis discussed a pipeline expected to yield 18 regulatory decisions over the next 24 months. The Swiss pharma currently has 139 ongoing pipeline projects, including 73 NMEs.
You may also be interested in...
The blockbuster leukemia drug will likely face generic competition in 2015, putting pressure on Novartis to bring new cancer drugs to market to make up for the lost sales. The company has several promising mid- to late-stage candidates in the pipeline, but developing another blockbuster the likes of Gleevec won’t be easy.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.